A phase II clinical trial of taxotere, emcyt and thalidomide (TET) for the treatment of hormone-refractory prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Docetaxel (Primary) ; Estramustine (Primary) ; Thalidomide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Oct 2005 New trial record.